Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Unit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland.
Nat Commun. 2022 Oct 18;13(1):6152. doi: 10.1038/s41467-022-33825-5.
We report the first long-term follow-up of a randomized trial (NCT04978259) addressing the effects of remdesivir on recovery (primary outcome) and other patient-important outcomes one year after hospitalization resulting from COVID-19. Of the 208 patients recruited from 11 Finnish hospitals, 198 survived, of whom 181 (92%) completed follow-up. At one year, self-reported recovery occurred in 85% in remdesivir and 86% in standard of care (SoC) (RR 0.94, 95% CI 0.47-1.90). We infer no convincing difference between remdesivir and SoC in quality of life or symptom outcomes (p > 0.05). Of the 21 potential long-COVID symptoms, patients reported moderate/major bother from fatigue (26%), joint pain (22%), and problems with memory (19%) and attention/concentration (18%). In conclusion, after a one-year follow-up of hospitalized patients, one in six reported they had not recovered well from COVID-19. Our results provide no convincing evidence of remdesivir benefit, but wide confidence intervals included possible benefit and harm.
我们报告了一项随机试验（NCT04978259）的首次长期随访结果，该试验旨在探讨瑞德西韦对 COVID-19 住院患者一年后康复（主要结局）和其他重要患者结局的影响。该试验在芬兰的 11 家医院招募了 208 名患者，其中 198 名患者存活，181 名（92%）完成了随访。一年时，瑞德西韦组和标准治疗组（SoC）的自我报告康复率分别为 85%和 86%（RR 0.94，95%CI 0.47-1.90）。我们推断瑞德西韦与 SoC 在生活质量或症状结局方面没有明显差异（p＞0.05）。在 21 种潜在的长新冠症状中，患者报告疲劳（26%）、关节痛（22%）、记忆力（19%）和注意力/专注力问题（18%）存在中度/重度困扰。总之，在对住院患者进行一年随访后，六分之一的患者报告 COVID-19 康复情况不佳。我们的结果没有提供瑞德西韦获益的令人信服证据，但置信区间较宽，包括可能的获益和危害。
